MedTrace Logo

Evaluation of Short Term Use of Experimental Eye Drops BHVI2, 0.02% Atropine and BHVI2 Plus 0.02% Atropine Eye Drops

NCT03690414 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2020-02-12

No results posted yet for this study

Summary

To assess the one-month ocular effects of nightly application of experimental BHVI2 and 0.02% atropine eye drops either alone or in combination, in children aged between 6 to 13 years old with myopia and randomized to use of experimental BHVI2 eye drops, 0.02% atropine eye drops, experimental BHVI2 plus 0.02% atropine eye drops.

Conditions

  • Myopia

Interventions

DRUG

Experimental BHVI2

Experimental BHVI2 eye drops

DRUG

Atropine sulfate 0.02% eye drops

Atropine eye drops

COMBINATION_PRODUCT

Combination eye drops

Combination eye drops with experimental BHVI2 plus 0.02% atropine

Sponsors & Collaborators

  • Brien Holden Vision

    collaborator INDUSTRY

  • Hai Yen Eye Care

    lead INDUSTRY

Principal Investigators

  • Huy D.M Tran, MD, MSc · Hai Eye Eye Care

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
13 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2019-02-02
Completion
2019-06-30

Countries

  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03690414 on ClinicalTrials.gov